

CURRICULUM VITAE

BRIAN B. BERGER, M.D.

Current Addresses:

Work:

Retina Consultants of Austin, PA Retina Consultants of Austin, PA
3705 Medical Parkway, Suite 410 1880 Round Rock Avenue, Ste 300
Austin, Texas 78705 Round Rock, TX 78681
512-454-5851 512-454-5851

Retina Research Center, PLLC
3705 Medical Parkway, Ste 420
Austin, Texas 78705
512-454-0138

Education:

Certifications:

Fellow, American Board of Ophthalmology

Fellowship:

Fellowship in Diseases of the Retina and Vitreous, Medical
College of Wisconsin, Milwaukee, Wisconsin, 1979 – 1980.

Residency:

Ophthalmology Residency, University of Illinois, Chicago,
Illinois, 1976 – 1979.

Internship:

Rotating Internship, Maricopa County General Hospital,
Phoenix, Arizona, 1975 – 1976.

Graduate:

University of Chicago, Chicago, Ill.
M.D., 1971 – 1975.

Undergraduate:


University of Illinois, Urbana, Ill.
Major: B.S. in Biology with high honors and high
distinction, 1967 – 1971.

Licenses:

Illinois 1976, 036-052947
Wisconsin 1979, 22289
Texas 1981, G0354

Organizations:

American Medical Association, 1974 – present
Texas Ophthalmological Assn., 1981 – present
Fellow, American Academy of Ophthalmology, 1981 – present
American Uveitis Society, 1978 – present
American Society of Retinal Surgeons, 1986 – present
Texas Affiliate of the American Diabetes Assn., 1984 – present
President, Capital Chapter, American Diabetes Association, 1987
President, Austin Ophthalmology Society, 1988-90
Austin Ophthalmology Society, 1984 – present
Association for Research in Vision and Ophthalmology, 1980 – present
Texas Medical Association, 1980 – present
Illinois Eye and Ear Infirmary Alumni Association, 1980 – present
Retina Society member, 1998 – present
Prevent Blindness Texas, Director, Austin, Texas, 2001 – 2003

 2/17/17

B. Berger, M.D.

Page 2

Honors:

Vitreous Society Honor Award, September 1997
American Academy of Ophthalmology Achievement
Award, 1999

Work History

Brian B. Berger, M.D., P.A., Austin, TX	1995 – present
Retina Research Center, Austin, TX	2007 - present
Retina Consultants of Texas, P.A., Austin, TX	1993 – 1995
Retina Clinic of Austin, Austin, TX	1984 – 1993
Scott & White Clinic, Temple, TX	1980 – 1984

Books Published and Authored:

Berger BB: Anterior Vitrectomy. Chapter 22, page 217, "Vitreoretinal Surgical Techniques," Gholam A. Peyman, Stephen A. Meffert, Famin Chou, Mandi D. Conway. Taylor and Francis, 2007.

Berger BB: Anterior Vitrectomy. Atlas of Vitreoretinal Surgery, GA Peyman, S Meffert, F Chou and M Conway. Martin Dunitz, Ltd., 2000.

Berger BB: Acute Iridocyclitis, Chronic Iridocyclitis, Intermediate Uveitis, Retinitis, Choroiditis, Panuveitis, Principles of Uveitis Treatment. Decision Making in Ophthalmology, WA van Heuven, JT Zwann. C.V. Mosby, 1992.

Berger BB: The lens, cataract and its management, Chapter 7, Principles and Practice of Ophthalmology. Edited by GA Peyman, DR Sanders and MF Goldberg. W.B. Saunders Co, Philadelphia, 1980.

Refereed Publications:

Jeffrey G. Gross, MD; Adam R. Glassman, MS; Lee M. Jampol, MD; Seidu Inusah, MS; Lloyd Paul Aiello, MD PhD; Andrew N. Antoszyk, MD; Carl W. Baker, MD; Brian B. Berger, MD; Neil M. Bressler, MD; David Browning, MD; Michael J. Elman, MD; Frederick L. Ferris, III MD; Scott M. Friedman, MD; Dennis M. Marcus, MD; Michele Melia, ScM; Cynthia R. Stockdale, MSPH; Jennifer K. Sun, MD, MPH; Roy W. Beck, MD, PhD and Diabetic Retinopathy Clinical Research Network. Panretinal Photocoagulation vs Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. *The Journal of the American Medical Association* 2015;314(20):2137-2146. doi:10.1001/jama.2015.15217.

Bressler SB, Michele M, Glassman AR, Almkhatar T, Bressler NM, Berger BB, Jampol LM, Shami M and Diabetic Retinopathy Clinical Research Network: Ranibizumab Plus Prompt or Deferred Laser for Diabetic Macular Edema in Eyes with Vitrectomy Prior to Anti-Vascular Endothelial Growth Factor Therapy. *Retina: The Journal of Retinal and Vitreous Diseases*; 2014

Berger BB, Mendoza W: Sclerotomy Closure for Retisert Implant. *Retina: The Journal of Retina and Vitreous Diseases*: February 2013 – Volume 33 – Issue 2 p 436-438.

Campochiaro PA, Channa R, Berger BB, et al. Treatment of diabetic macular edema with a designed

- ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. *Am J Ophthalmol* 155:697-704, 2013
- Krzystolik MG, Strauber SF, Aiello LP, Beck RW, Berger BB, Bressler NM, Browning DJ, Chambers RB, Danis RP, Davis MD, Glassman AR, Gonzalez VH, Greenberg PB, Gross JG, Kim JE, Kollman C and Diabetic Retinopathy Clinical Research Network: Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. *Ophthalmology*.2007 Aug;114(8):1520-5
- Chan CK, Berger BB, Joondeph BC, Diagnostic and Therapeutic Challenges. *Retina: The Journal of Retinal and Vitreous Diseases*; 27(1): 101-105.
- Banker AS, Freeman WR, Azen SP, Lai MY and the Vitrectomy for Macular Hole Study Group: A Multicentered clinical trial of serum as adjuvant therapy for surgical treatment of macular holes. *Archives of Ophthalmology* 1999; 117 (11): 1499, 1999.
- Freeman WR, Kim JW, Azen SP, Wael EH, Mishell MS, Bailey, IL, The Vitrectomy for Macular Hole Study Group: Vitrectomy for the treatment of full-thickness stage III or IV macular holes: Results of a multicentered randomized clinical trial. *Archives of Ophthalmology* 1997; 115: 11-21.
- Banker AS, Freeman WR, Kim JW, Azen SP, Munguia D, The Vitrectomy for Macular Hole Study Group: Vision threatening complications of surgery for full thickness macular holes. *Ophthalmology* 1997; 115: 1214-1215.
- Moorthy RS, Weinberg DV, Teich SA, Berger BB, Minturn JT, Kumar S, Rao NA, Fowell SM, Loose LA, Jampol LM: Medical and surgical management of progressive outer retinal necrosis (PORN) in acquired immunodeficiency syndrome. *Br. J. Ophthalmol.* 81: 189-194, 1997.
- Kim JW, Freeman WR, Wael EH, Klein DJ, Azen SP, Bailey, IL, The Vitrectomy for Macular Hole Study Group: Prospective randomized trial of vitrectomy versus for observation for stage II macular holes. *Am J Ophthalmol* 121: 605614, 1996.
- Kim JW, Freeman WR, Wael EH, Macquire, Arevalo F, Azen SP, Bailey, IL, The Vitrectomy for Macular Hole Study Group: Baseline characteristic, natural history and risk factors to progression in eyes with stage II macular holes. *Am J Ophthalmol* 102: 1818-29, 1995.
- De Bustros S, Freeman WR and the Vitrectomy for Prevention of Macular Hole Study Group: Vitrectomy for prevention of macular hole trial: results of a randomized multicenter trial. *Ophthalmology* 101: 1055-1060, 1994.
- Berger BB, Egwuagu CE, Freeman WR, Wiley CA: Miliary toxoplasmic retinitis in acquired immunodeficiency syndrome. *Arch Ophthalmol* 111: 373-376, 1993.
- Berger BB, Heads Up: Legal Case May Affect Valuing of Medical Practices, Letter to the Editor, *Texas Medicine* 88(10): 9, 1992.
- Sneed SR, Blodi CF, Berger BB, Speights JW, Folk JC, Weingeist TA: Pneumocystis carinii choroiditis in patients receiving inhaled pentamidine. *New England Journal of Medicine* 322: 936-937, 1990.
- Holland GN, Engstrom RE, Glasgow BJ, Berger BB, Daniels SA, Sidikaro Y, Harmon JA, Fischer DH, Boyer DS, Rao NA, Eagle RC, Kreiger AE, and Foos RY: Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome.

B. Berger, M.D.

Page 4

Am J Ophthalmol 106: 653-667, 1988.

Berger BB: Eye color affects cyclocryotherapy-induced inflammation. *Ophthalmic Surgery* 16: 206, 1985.

Berger BB: Letter to editor re: Successful treatment of postoperative candida endophthalmitis in an eye with an intraocular lens implant. *Am J Ophthalmol* 98: 648-649, 1984.

Berger BB: Foveal photocoagulation from laser iridotomy. *Ophthalmol* 91: 1029-1033, 1984.

Berger BB: Branch vein occlusion: Traction macular detachment. *Ann Ophthalmol* 16: 623-624, 1984.

Berger BB: Repeater unit for laser surgery. *Am J Ophthalmol* 97: 104, 1984.

Berger BB; The laser in ophthalmology. *Texas Medicine*, October 1982.

Dieckert JP and Berger BB: Prostatic carcinoma metastatic to the choroid. *Brit J Ophthalmol* 66: 234-239, April 1982.

Berger BB: Endophthalmitis complicating neonatal Group B streptococcal septicemia. *Am J Ophthalmol* 92: 681-684, 1981.

Berger BB and Reeser F: Retinal pigment epithelial detachments in posterior scleritis. *Am J Ophthalmol* 90: 604, 1980.

Berger BB, Tessler H and Kottow M: Anterior segment ischemia in Fuchs' Heterochromic cyclitis. *Arch Ophthalmol* 98: 499, 1980.

Berger BB, Zweig KO and Peyman GA: Vitreous loss managed by anterior vitrectomy: Long-term follow-up of 59 cases. *Arch Ophthalmol* 98: 1245, 1980.

Berger BB, Weinberg RS, Tessler HH, Vygantus CM, and Wyhinny G: Bilateral cytomegalovirus panuveitis following high dose steroid therapy. *Am J Ophthalmol* 88: 1020, 1979.

Berger BB and Frankel M: Complete third nerve paralysis and decreasing vision secondary to subdural hematoma. *Ann Ophthalmol* 11: 1817, 1979.

Berger BB, Peyman GA, Juarez C, Mason G and Raichand M: Massive retinal gliosis clinically simulating a choroidal melanoma. *Canad J Ophthalmol* 14: 285, 1979.

Berger BB, Wainer BH, Bonese KF, Schuster CW, Fitch FW, and Rothberg RM: The interaction of morphine with sera from monkeys physically dependent on morphine. *Clin Immunol Immunopath* 4: 317, 1975.

Non-Refereed Publications:

Saradha Chexal, MD, Ivana Gunderson, BS, Brian B. Berger, MD, Chirag Jhaveri, MD. A Novel Retina Today, May/June 2016 72-78.

Gunderson I., Corak B., Berger BB. Designing a Clinic and a Research Center Side By Side. *New Retina MD*. 2014; 5(3): 27-30.

B. Berger, M.D.

Page 5

Berger BB, Gunderson I, Rickman CB, Lin J, Garzone P. An Investigational Therapy for Geographic Atrophy in Age Related Macular Degeneration. *Retina Today*. 2014; 9(4): 73-75.

Berger BB Fluocinolone Implant for Idiopathic Non-Infectious Posterior Uveitis. *Retinal Physician*. 2012 May: 2-6, 2012.

Berger BB, Corak I: Sustained-Release Steroidal Implants for the Treatment of Uveitis. *Advanced Ocular Care* January/February; 35-36, 2011.

Berger BB: Anterior Vitrectomy Aids Cataract Surgery Complications. *Ophthalmology Times* 26: 8-13, 2001.

Berger BB: How to Manage Iridocyclitis. *Review of Ophthalmology*, August 1995.

Berger BB, Jeffcoat W and McCollum T: Irrigating contact lens. *Ocutome/Fragmatome Newsletter* 7 (3): 1, 1982.

Scientific Posters:

Effect of selective oral inhibition of CCR2/5 chemokine receptors compared to intravitreal ranibizumab on diabetic macular edema (DME). Association for Research in Vision and Ophthalmology Annual Meeting, Seattle, WA May 2016.

Efficacy of RTH258 (ESBA1008), an Anti-VEGF Agent, Applied by Microvolume Injection or Infusion in Subjects With Neovascular AMD. Association for Research in Vision and Ophthalmology Annual Meeting, Denver, CO, May 2015.

Phase I, Masked, Placebo-Controlled, Single and Multiple Ascending Intravenous Dose Studies Evaluating Systemic and Ocular Safety, Tolerability, and Visual Acuity Effects of RN6G (PF-04382923) in Subjects with Dry, Age-Related Macular Degeneration (ARMD). Retina Society, Beverly Hills, CA, September 2013.

Sclerotomy Closure for Retisert Implant, Brian B. Berger, Winnie Mendoza. Retina Society Annual Meeting, Washington D.C., October 2012.

Year 7 Outcomes For Ranibizumab-treated Subjects In Anchor/marina: A Multicenter, Prospective Cohort Study. Fort Lauderdale, FL, May 2012

A Multicenter Phase I Clinical Trial Targeting Tissue Factor with *hl-con1*TM for the Treatment of Neovascular Age Related Macular Degeneration. Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, FL, May 2012.

Retinal Thickness in People with Diabetes and Minimal or No Diabetic Retinopathy as Measured by Heidelberg Spectralis Optical Coherence Tomography. Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, FL, May 2012.

A Phase I/II Study of Oral Pazopanib, a Receptor Tyrosine Kinase Inhibitor, in Neovascular Age Related Macular Degeneration. Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, FL, May 2012.

Single Ascending Doses of DARPin®, MP0112, Show Potential for Quarterly Dosing in DME, Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, FL, May 2011. Manjula Patel, Brian B. Berger, Jeffrey S. Heier, David M. Brown, Peter A. Campochiaro, Michael T. Stumpp. Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, FL, May 2011.

B. Berger, M.D.

Page 6

Anti-VEGF Treatment Patterns Among Age-related Macular Degeneration Patients in U.S. Clinics: The PRACTICE Study. American Academy of Ophthalmology, Chicago, IL, October 2010.

A Phase 2 Randomized, Double-Masked Study Comparing the Safety and Efficacy of Topical ATG003 1% and 3% Solutions to Placebo in Wet ARMD (OPTIMA Study). ASRS 26th Annual Meeting, Maui, Hawaii, October 2008.

Photodynamic Therapy for Classic Choroidal Neovascularization Secondary to Juxtafoveal Telangiectasis. Vitreous Society 18th Annual Meeting, Cancun, Mexico, January 2000.

Retinal manifestations of *Bartonella Henselae*. American Academy of Ophthalmology Annual Meeting, October 1997, San Francisco, California.

Retinal manifestations of *Bartonella Henselae*. XX Meeting of the Club Jules Gonin, Bern, Switzerland, September 1997.

Stem cell assay of choroidal melanoma. American Academy of Ophthalmology Annual Meeting, Chicago, October 1983.

Academic Appointments:

Clinical Assistant Professor of Ophthalmology, Texas A&M University College of Medicine, 2014-present

Clinical Professor of Ophthalmology, University of Texas Health Science Center at San Antonio, 1998 – present.

Clinical Asst. Professor of Ophthalmology, University of Texas Health Science Center at San Antonio, 1984 – 1997.

Assistant Professor of Surgery, Texas A&M University, College of Medicine, 1981 – 1983.

Instructor, Department of Ophthalmology, Medical College of Wisconsin, 1979 – 1980.

Instructor in Ophthalmology, University of Illinois, 1978 – 1979.

Teaching:

Community Preceptor Ambulatory Community Selective. UTMB, Galveston, TX, 2005 – present.

Chief, Uveitis Consultation Service; core curriculum in uveitis. University of Texas Health Science Center at San Antonio, 1984 – present.

Anterior Vitrectomy Techniques for the Comprehensive Ophthalmologist, Course Director, American Academy of Ophthalmology, Orlando, Florida, October 1999.

Anterior Vitrectomy Techniques for the Comprehensive Ophthalmologist, Course Director, American Academy of Ophthalmology, New Orleans, Louisiana, November 1998.

An Algorithmic Approach to Posterior Uveitis, Course Director, American Academy of Ophthalmology, San Francisco, California, October 1997.

An Algorithmic Approach to Posterior Uveitis, Course Director, American Academy of Ophthalmology, Chicago, Illinois, October 1996.

B. Berger, M.D.

Page 7

An Algorithmic Approach to Posterior Uveitis, Course Director, American Academy of Ophthalmology, Atlanta, Georgia, October 1995.

An Algorithmic Approach to Posterior Uveitis, Course Director, American Academy of Ophthalmology, San Francisco, California, November 1994.

An Algorithmic Approach to Posterior Uveitis, Course Director, American Academy of Ophthalmology, Chicago, Illinois, November 1993.

An Algorithmic Approach to Posterior Uveitis, Course Director, American Academy of Ophthalmology, Dallas, Texas, November 1992.

The Management of Posterior Uveitis for the Practicing Ophthalmologist, Course Director, American Academy of Ophthalmology, Anaheim, California, October 1991.

The Management of Posterior Uveitis for the Practicing Ophthalmologist, Course Director, American Academy of Ophthalmology, Atlanta, Georgia, October 1990.

The Management of Posterior Uveitis for the Practicing Ophthalmologist, Course Director, American Academy of Ophthalmology, New Orleans, Louisiana, October 1989.

Vitrectomy Workshop, Course Director, Scott and White Clinic and Texas A&M University College of Medicine, Austin, Texas, October 1983.

Macular Degeneration Update, Course Director, Scott and White Clinic and Texas A&M University College of Medicine, Temple, Texas, September 1982.

Vitrectomy course, instructor, Medical College of Wisconsin, Milwaukee, Wisconsin, May 1980.

Clinical Research:

Principal Investigator: Simultaneous Blockade of Angiopoietin-2 and VEGF-A with the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration (F. Hoffman-La Roche Ltd., CR29521 Stairway)

Principal Investigator: A Phase II, Multicenter, Randomized, Active-Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration (F. Hoffman-La Roche Ltd, GX28228 Ladder)

Sub-Investigator: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Pilot Study to Evaluate Effects of Emixustat Hydrochloride on Aqueous Humor Biomarkers Associated with Proliferative Diabetic Retinopathy (Acucela Inc., 4439-203)

Principal Investigator: A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122 Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration (Santen Inc., PAVE study)

Sub- Investigator: A Randomized, Double Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular Age-Related Macular Degeneration (Regeneron Pharmaceutical, Inc, R910-3-AMD-1517 ONYX)

Principal Investigator: A randomized, multi-center, single masked, sham controlled, proof-of-concept study of intravitreal CLG561 as a monotherapy and in combination with LFG316 in subjects with geographic atrophy (Alcon Research, LTD, CLG561-2201)

Sub-Investigator: A Multiple-Center, Multiple-Doses, Randomized, Active Comparator-Controlled, Double-Masked, Parallel-Group, 28-Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients with Diabetic Macular Edema (Genentech BP30099 Boulevard)

Sub-Investigator: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients with Geographic Atrophy (GA) - FILLY – (Apellis Pharmaceuticals, Inc., POT-CP121614)

Sub-Investigator: A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Non-Inferiority Study of X-82 plus *prn* Eylea® Compared to *prn* Eylea® Monotherapy in Neovascular AMD (Tyrogenex, Inc., X82-OPH-201)

Principal Investigator: A Phase II Proof-of-Concept Study of the Safety and Efficacy of HuCNS-SC Subretinal Transplantation in Subjects with Geographic Atrophy of Age-Related Macular Degeneration (StemCells, Inc., CL-AMD-201)

Principal Investigator: A Phase 2 Multicenter, Randomized, Controlled, Double-Masked Clinical Trial Designed to Evaluate the Safety and Exploratory efficacy of Luminite® (ALG-1001) as Compared to Avastin® in the Treatment of Diabetic Macular Edema (Allegro Ophthalmics, LLC, DME 202B)

Principal Investigator: Clinical Study Protocol Phase I Dose Escalation and Expansion Study of DS-7080a in Subjects with Neovascular Age-Related Macular Degeneration (Daiichi Sankyo Pharma Development, DS7080-A-U101)

Principal Investigator: A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (Genentech BP29647 Avenue)

Principal Investigator: Genes in Diabetic Retinopathy Project (DRCR Genetics)

Sub-Investigator: Prospective, Multicenter Post-Approval Study (PAS) of Visioncare's Implantable Miniature Telescope (By Dr. Isaac Lipshitz) in Patients with Bilateral Severe to Profound Central Vision Impairment Associated with End-Stage Age-Related Macular Degeneration (VisionCare Ophthalmic Technologies, IMT-PAS-01)

Sub-Investigator: A Randomized, Double Masked, Three Dose Safety and Pharmacokinetic Study of RTH258 Following Intravitreal (IVT) Injection in Subjects with Neovascular Age-Related Macular Degeneration (Alcon Research, Ltd., RTH258-E003)

Principal Investigator: An open-label single ascending dose and randomized double-masked, ranibizumab controlled, safety, tolerability, and efficacy study of intravitreal LMG324 in subjects with neovascular age-related macular degeneration (Alcon Research, LTD, LMG324-2201)

Sub-Investigator: A Phase 4 Safety Study of IOP Signals Inpatients Treated with Iluvien® (Fluocinolone Acetonide Intravitreal Implant) 0.19 MG (Alimera Sciences, Inc., M-01-15-004)

B. Berger, M.D.

Page 9

Sub-Investigator: Prospective, observational longitudinal study addressing Peripheral Diabetic Retinopathy (DR) Lesions on Ultrawide-field Fundus Images and Risk of DR Worsening Over Time (DRCR Protocol AA)

Principal Investigator: A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration (Alcon Research Ltd. RTH258-C001)

Principal Investigator: A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients with Choroidal Neovascularization Secondary to Age-related Macular Degeneration (Iconic Therapeutics IT-002)

Principal Investigator: A Phase 2, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema (Astellas Pharma Europe B.V. VID1)

Sub-Investigator: A randomized, parallel group, double-masked, active-controlled Phase 1/2 clinical trial to evaluate the efficacy and safety of dexamethasone sodium phosphate Visulex system for the treatment of non-infectious anterior uveitis (Aciont, Inc. DSPV-201)

Principal Investigator: A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patient with Geographic Atrophy Secondary to Age-Related Macular Degeneration (Genentech GX29176 Chroma)

Principal Investigator: Study of Comparative Treatments for Retinal Vein Occlusion 2 [SCORE2]: A Multicenter, Prospective, Randomized Non-Inferiority Trial of Eyes with Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 weeks with Intravitreal Aflibercept Every 4 weeks (SCORE2)

Principal Investigator: A Randomized, Double Masked, Placebo Controlled Study Evaluating ORACEA® in Subjects with Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration (University of Virginia Department of Ophthalmology TOGA)

Principal Investigator: A Phase 1 Open-Label, Multi-Center Trial with Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients with Neovascular Age-Related Macular Degeneration (AMD) (Panoptica PAN-90806)

Principal Investigator: A Phase 2, Randomized, Active- Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects with Diabetic Macular Edema (Aerpio AKB-9778):

Sub-Investigator: Ocriplasmin Research to Better Inform Treatment (Thrombogenics TG-MV-018 ORBIT)

Sub-Investigator: Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity (DRCR Protocol V)

Principal Investigator: Short-term Evaluation of Combination Corticosteroid+Anti-VEGF Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy in Pseudophakic Eyes (DRCR Protocol U)

Sub-Investigator: A Randomized, Multicenter, Double-Masked, Parallel-Group Study Comparing the

Safety and Efficacy of BOL-303259-X 0.024% (Latanoprostene Bunod) Ophthalmic Solution with Timolol Maleate Ophthalmic Solution 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension (Bausch & Lomb APOLLO)

Principal Investigator: A Phase 3, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreal Administration of Fovista (Anti PDG-F Pegylated Aptamer) Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration (Ophthotech Corp. OPH1003)

Principal Investigator: A prospective, Two Cohort, Single-Masked, Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection or Infusion in Subjects with Exudative Age-Related Macular Degeneration (Alcon C-13-001 ESBA1008)

Principal Investigator: An Open-Label, Non-randomized, Single-Arm, Roll-Over Study to Continue Dosing of Gevokizumab in Non-Infectious Intermediate, Posterior, or Pan- Uveitis Patients Who Each Successfully Completed either the X052130 or the X052131 Study (XOMA X052132)

Principal Investigator: A Randomized, Placebo-Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral Optina in Adults Patients with Diabetic Macular Edema (Ampio Pharmaceuticals, Optina Danazol Oral Capsule Clinical Study AP-05-002)

Principal Investigator: A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel Group, Multi Center, Study to Compare the Efficacy and Safety of a Chemokine CCR2/5 Receptor Antagonist (PF-04634817) with that of Ranibizumab in Adult Subjects with Diabetic Macular Edema (Pfizer PF-04634817)

Principal Investigator: A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema (DRCR Protocol T)

Principal Investigator: A Phase II, Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Multi Dose Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of RN6G (PF-04382923) in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration (Pfizer B1181003)

Principal Investigator: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis (XOMA X052130)

Principal Investigator: A Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled with Systemic Treatment (XOMA X052131)

Principal Investigator: A Randomized, Multi-center, Phase II Study of the Safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination with Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema with Involvement of the FoveAL Center (Juvenile Diabetes Research Foundation International iDEAL Study)

Principal Investigator: An Open-label Dose Escalation Study of PF-04523655 (Stratum I) Combined With a Prespective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating the Efficacy and Safety of PF-04523655 Alone and in Combination with Ranibizumab Versus Ranibizumab Alone in Diabetic Macular Edema (Quark, MATISSE Study)

Principal Investigator: Safety and Tolerability Study of RN6G In Subjects With Advanced Dry, Age-

Related Macular Degeneration Including Geographic Atrophy (Pfizer B1181002)

Principal Investigator: A 12-Month, Multicenter, 2 Stage (Open Label, Dose-Escalation, Followed by Masked, Randomized) Single Dose Study of the Safety and Efficacy of AGN-208397 in Patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO) (Allergan 208397-001)

Principal Investigator: A Phase 2, Study to Investigate GSK933776 in Adult Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (GlaxoSmithKline BAM114311)

Principal Investigator: Multiple Dose of the Safety and Efficacy of AGN-150998 in Patients with Exudative Age-Related Macular Degeneration (Allergan REACH)

Principal Investigator Effect of Diabetes Education during Retinal Ophthalmology Visits on Diabetes Control (DRCR M)

Principal Investigator: To Determine if Vision Outcome at Two Years in Eyes with PDR (with or without concurrent DME) that Receive Anti-VEGF Therapy with Deferred PRP are Non-Inferior to Those in Eyes that Receive Standard Prompt PRP Therapy (DRCR Protocol S)

Principal Investigator: A Randomized, Sham-controlled, Double-masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (Thrombogenics TG-MV-014)

Principal Investigator: Controlled Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered Monthly or Every Other Month to Patients with Geographic Atrophy (Genentech (Mahalo) FCFD4514S)

Principal Investigator: A Phase 3 Multicenter, Randomized, Double-Masked Study of the Safety and Efficacy of Difluprednate 0.05% Ophthalmic Emulsion Compared to Prednisolone Acetate 1% Ophthalmic Suspension in the Treatment of Endogenous Anterior Uveitis (Alcon C-10-034)

Principal Investigator: To Evaluate Pazopanib Eye Drops Administered for 12 Weeks to Patients with Neovascular Age Related Macular Degeneration (GlaxoSmithKline MD7114987)

Principal Investigator: Phase 2A, Multi-Center, Masked, Randomized, Comparator-Controlled Study Evaluating ISONEPTM (SONEPCIZUMAB [LT1009]) As Either Monotherapy Or Adjunctive Therapy To LUCENTIS OR AVASTIN VS LUCENTIS OR AVASTIN Alone for the Treatment of Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (Lpath LT1009-Oph-003 (NEXUS)

Principal Investigator: A Phase 1B Multi-Center, Open-Label, and Randomized Study of Isoneptm Administered as Intravitreal Injections to Subjects with PED Secondary to Exudative Age-Related Macular Degeneration or Polypoidal Choroidal Vasculopathy. (LPath LT1009-Oph-002)

Principal Investigator: A Phase 1 / 2 Trial to Investigate the Safety and Tolerability of Single and Repeated Doses of hI-con1 Following Administration by Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration (AMD) (Iconic IT-001)

Principal Investigator: Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema (Alimera C0105001)

Principal Investigator: An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (DRCR N)

Principal Investigator: A Multi-center, Double-Masked, Parallel Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Noninfectious Intermediate, Posterior or Pan-uveitis (LUX BioSciences – LX211-11)

Principal Investigator: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Inactive Non-infectious Intermediate-, Posterior-, or Pan-uveitis, 2010. (Abbott – M10-880)

Principal Investigator: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Active Non-infectious Intermediate-, Posterior-, or Pan-uveitis, 2010. (Abbott – M10-877)

Principal Investigator: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Active Non-infectious Intermediate-, Posterior-, or Pan-uveitis, 2010. (Abbott – M11-327)

Sub-Investigator: A Phase IIb, Randomized, Double Blind, Two-Arm, Multi-Center. Placebo-Controlled, Study to Assess the Efficacy and Safety of EN324 (Axomadol) in Subjects with Moderate to Severe, Chronic Low Back Pain (CLBP), 2010. (Endo Pharmaceuticals EN3324-201).

Sub-Investigator: An Open-Label Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Exploratory Efficacy and Pharmacodynamics of Oral Pazopanib Administered for 28 Days to Neovascular Age-Related Macular Degeneration Patients, 2010. (GlaxoSmithKline - MD1114155).

Principal Investigator: A Randomized, Multicenter, Double Blind, Parallel-Group Trial to Assess the Analgesic Efficacy and Safety of a New Analgesic Compared With Placebo in Subjects With Painful Diabetic Peripheral Neuropathy, 2010. (Grünenthal -KF0151Y/10).

Principal Investigator: Phase II Multi Center, Prospective, Randomized, Age Related Macular Degeneration, Comparator Controlled, Dose Ranging Study Evaluating PF-04523655 Versus Ranibizumab in the Treatment of Subjects with Choroidal Neovascularization, 2010. (Pfizer – Monet - B0451011)

Principal Investigator: Controlled, Double-Masked, Randomized, Multicenter Study to Evaluate AL-78898A as a Treatment of Exudative AMD, 2010. (Alcon: C-09-067 (Race)).

Principal Investigator: Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects with Geographic Atrophy, 2009. (Acucela: 4429-201).

Principal Investigator: Study of MP0112 Intravitreal Injection in Patients with Diabetic Macula Edema, 2010. (Molecular Partners: MP0112-CP02).

Principal Investigator: A Pilot Study in Individuals with Center-Involved DME Undergoing Cataract Surgery, 2009. (Diabetic Retinopathy Clinical Research (DRCR): Protocol P)

Principal Investigator: An Observational Study in Individuals with Diabetic Retinopathy without Center-Involved DME Undergoing Cataract Surgery, 2009. (Diabetic Retinopathy Clinical Research (DRCR): Protocol Q).

Sub-Investigator: A Randomized, Double-Blinded, Placebo-Controlled, Parallel Group, Multi-center, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110 mcg in Adults and Adolescents 12 Years of Age and Older with Perennial Allergic Rhinitis, 2009. (GlaxoSmithKline – FFR110537).

B. Berger, M.D.

Page 13

Principal Investigator: A Phase I/II Prospective, Randomized, Double masked, Vehicle and Comparator Controlled, Dose Ranging Study of CP-690,550 in Subjects with Dry Eye Disease, 2009. (Pfizer A3921034).

Principal Investigator: A Phase I, Double-Masked, Placebo-Controlled Study Evaluating the Safety, Tolerability, Immunogenicity Pharmacokinetics and Pharmacodynamics of Multiple Escalating Dosages of RN6G in Subjects With Advanced Dry, Age-Related Macular Degeneration (ARMD) Including Geographic Atrophy, 2009. (Pfizer – B1181002).

Principal Investigator: A Randomized, Placebo-Controlled, Double Masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion, 2008. (ThromboGenics – TG-MV-007).

Principal Investigator: A Phase II, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy, 2008. (MacuSight DR-002 – Diamond).

Principal Investigator: A Phase II, Randomized, Masked, Controlled Study to Assess the Safety and Efficacy of Lucentis plus Sirolimus versus Lucentis plus Placebo in Patients with Sub-foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration, 2008. (MacuSight DR-003 – Emerald).

Sub-Investigator: A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multi-center Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adolescent and Adult Subject with Asthma, 2008. (GlaxoSmithKline – Topsail – HZA106839).

Principal Investigator: A double-masked, randomized, controlled study of the safety, tolerability, and biological effect of repeated intravitreal administration of VEGF Trap-Eye in patients with Diabetic Macular Edema (DME), 2008. (Regeneron 0706 – BB-IND 100083)

Principal Investigator: A Non-Treatment Study of Risk Factors for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), 2008. (Pfizer – A1481259 – NAION)

Principal Investigator: A Phase III, Double-Masked, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically, 2007. (Genentech – Rise FVF4170g).

Principal Investigator: A Phase III, multi-center, randomized, sham injection-controlled study of the efficacy and safety of Ranibizumab injection compared with sham in subjects with Macular Edema secondary to Branch Retinal Vein Occlusion, 2007. (Genentech – BRAVO FVF4165g).

Principal Investigator: A Phase III, multi-center, randomized, sham injection-controlled study of the efficacy and safety of Ranibizumab injection compared with sham in subjects with Macular Edema secondary to Central Retinal Vein Occlusion, 2007. (Genentech – CRUISE FVF4166g).

Principal Investigator: A Phase 3, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis®, compared with Lucentis® monotherapy every 4 weeks in patients with Exudative Age-Related Macular Degeneration (AMD), 2007. (Cobalt ACU301)

Principal Investigator: A Phase II Randomized, Double-Masked, Study Comparing the Safety and Efficacy of ATG003 (Mecamylamine HCL) 1.0% and 0.3% Ophthalmic Solutions to Placebo in Patients with Neovascular ("WET") Age-Related Macular Degeneration (NV-AMD), 2007. (Athenagen ATG203-201).

Principal Investigator: Intravitreal Administration of Two VEGF Trap Formulations in Subjects with Neovascular Age Related Macular Degeneration, 2007. (Regeneron 0603)

Principal Investigator: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration, 2007. (Regeneron – VGFT-OD-0605)

Principal Investigator: An Open-Label, Long-Term, Safety, and Tolerability Study of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration, 2007. (Regeneron – VGFT-OD-0702)

Principal Investigator: A Randomized, Prospective, Active Controlled, Study of the Epi-Rad90™ Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization Associated with Wet Age-Related Macular Degeneration, 2007. (NeoVista – NV-114-07 Cabernet).

Principal Investigator: A Phase 2 Randomized, Double-Masked, Study to Evaluate the Safety and Preliminary Efficacy of ATG003 in Patients with Neovascular Age-Related Macular Degeneration (NV-AMD) Receiving Frequent Maintenance Intravitreal Anti-VEGF Antibody Therapy (Ranibizumab or Bevacizumab), 2007. (CoMentis Inc. ATG203-203).

Principal Investigator: LX211 as Therapy in Subjects with Active Sight Threatening, Non-infectious Intermediate-, Anterior- and Intermediate-, Posterior-, or Pan-Uveitis, 2007. (Lux 01)

Principal Investigator: LX211 as Therapy in Subjects with Clinically Quiescent Sight Threatening, Non-infectious, Intermediate-, Anterior- and Intermediate-, Posterior-, and Pan-Uveitis, 2007. (Lux 02)

Principal Investigator: LX211 as Therapy in Subjects with Active Sight Threatening, Non-infectious Anterior Uveitis, 2007. (Lux 03)

Principal Investigator: Randomized 700 µg and 300 µg DEX PS DDS Compared with a Sham for the Treatment of Non-infectious Ocular Inflammation of the Posterior Segment in Patients with Intermediate or Posterior Uveitis, 2007. (Allergan Uveitis 014)

Principal Investigator: A 24-month randomized, double-masked, controlled, multicenter, phase IIIB study assessing safety and efficacy of Verteporfin (Visudyne®) photodynamic therapy administered in conjunction with Ranibizumab (Lucentis®) versus Ranibizumab (Lucentis®) monotherapy in patients with Subfoveal Choroidal Neovascularization secondary to Age-Related Macular Degeneration, 2007. (Novartis – Denali – BPD952A CBPD952A2308).

Principal Investigator: Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination with Laser Photocoagulation for Diabetic Macular Edema, 2007. (DRCR-I).

Principal Investigator: Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy, 2007. (DRCR-J)

Principal Investigator: Course of Response to Focal Photocoagulation for Diabetic Macular Edema, 2007. (DRCR-K)

Principal Investigator: A randomized, multicenter, placebo-controlled, double masked, parallel-group study to assess the tolerability, safety and efficacy of 2 weeks oral AEB71 300 mg twice daily, followed by 6 weeks oral AEB071 200 mg twice daily in the treatment of Macular Edema in patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Pan Uveitis, 2007. (Novartis – Uveitis – AEB071).

B. Berger, M.D.

Page 15

Principal Investigator: A 3-Year, Phase III, multi-center, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the treatment of patients with Diabetic macular Edema, 2006. (Allergan DME).

Principal Investigator: Randomized ASI-001A 0.5 µg/day and ASI-001B 0.2 µg/day Fluocinolone Acetonide Intravitreal Inserts Versus a Sham Injection for Subjects with Diabetic Macular Edema, 2006. (Alimera FAME)

Principal Investigator: Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema using Bevacizumab (Avastin), 2006. (DRCR-H)

Principal Investigator: Evaluation of Vitrectomy for Diabetic Macular Edema, 2006. (DRCR-D)

Principal Investigator: Intravitreal Triamcinolone Acetonide versus Laser Photocoagulation for Subjects with Diabetic Macular Edema, 2006. (DRCR-B)

Principal Investigator: Laser Photocoagulation for Subjects with Diabetic Macular Edema, 2006. (DRCR-A)

Principal Investigator: Longitudinal Database to Capture Patient Demographics and Treatment Outcomes in Patients with CNV Secondary to AMD, 2005 (InSight)

Principal Investigator: Visudyne Plus Two Different Dose Regimens of Intravitreal Triamcinolone Acetonide versus Visudyne plus Macugen in Subjects with CNV Secondary to AMD, 2005 (Veritas, Novartis)

Principal Investigator: An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Who Have Completed the Treatment Phase of a Genentech-Sponsored Ranibizumab Study, 2005. (Genentech – HORIZON FVF3426g).

Principal Investigator: Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with CNV Secondary to AMD, 2005 (Sailor)

Principal Investigator: Pegaptanib Sodium Intravitreal Injection in patients with Macular Edema secondary to Central Retinal Vein Occlusions, 2005 (Eyetechn).

Principal Investigator: Squalamine Lactate Injection administered for treatment of Subfoveal Choroidal Neovascularization secondary to Age-Related Macular Degeneration, 2005 (Genaera).

Principal Investigator: Cand5 Intravitreal Injection administered for treatment of Subfoveal Choroidal Neovascularization secondary to Wet Age-Related Macular Degeneration, 2005 (Acuity, CARE).

Sub-Investigator: Dexamethasone Posterior Segment Drug Delivery System Applicator in patients with Macular Edema secondary to Retinal Vein Occlusions, 2005 (Allergan RVO).

Principal Investigator: Microcurrent Stimulation for Non-exudative Age-Related Macular Degeneration, 2004 (CibaVision, MCS-500).

Principal Investigator: Visudyne administered in conjunction with Intravitreal Triamcinolone Acetonide in Minimally Classic or Occult Subfoveal Neovascularization in Age Related Macular Degeneration, 2004 (VisTA).

Principal Investigator: Standard Care vs. Corticosteroid for Retinal Vein Occlusion

B. Berger, M.D.

Page 16

(SCORE) Study, 2004 (Allergan).

Sub-Investigator: Dexamethasone Posterior Segment Drug Delivery System Applicator in patients with Diabetic Macular Edema, 2004 (Allergan DME)

Principal Investigator: Ranibizumab in Predominantly Classic Subfoveal Neovascularization in Age-Related Macular Degeneration, 2004 (Genentech, Anchor).

Sub-Investigator: Effects of Ciclesonide and Beclomethasone on Lens Opacification in Adult Subjects with Moderate to Severe Persistent Asthma, 2004 (PPD Development, Aventis).

Sub-Investigator: Long-Term Safety of Ciclesonide Applied in the Treatment of Perennial Allergic Rhinitis, 2004 (Altana Pharma).

Principal Investigator: Laser Photocoagulation for Diabetic Macular Edema, 2003. (Diabetic Retinopathy Clinical Research Network).

Principal Investigator: Ranibizumab in Minimally Classic or Occult Subfoveal Neovascularization in Age Related Macular Degeneration, 2003 (Genentech, Marina).

Principal Investigator: A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser photocoagulation for Diabetic Macular Edema, 2002. (Diabetic Retinopathy Clinical Research Network).

Principal Investigator: Visudyne in Occult Choroidal Neovascularization, 2002 (QLT, Inc./VIO).

Principal Investigator: Retisert in Chronic Diabetic Macular Edema, 2002 (Control Delivery Systems).

Principal Investigator: Phase II Study for Dexamethasone Implant for Persistent Macular Edema, 2002 (Oculex).

Principal Investigator: Envision Steroid Implant for Non-Infectious Uveitis, 2002 (Bausch & Lomb).

Principal Investigator: Visudyne (verteporfin) in Age-Related Macular Degeneration Trial, 1999 (Cibavision, Inc.).

Principal Investigator: Prophylactic Treatment for Age-Related Macular Degeneration Trial, 1999

Certified Surgeon: Perfluoron Clinical Trial, 1995-1996 (Escalon, Inc.).

Principal Investigator: Oral Ganciclovir Maintenance Therapy for CMB Retinitis Trial, 1994 (Syntex Pharmaceutical Co.).

Certified Surgeon: Vitrectomy for Macular Hole Study, 1992 – 95.

Certified Surgeon: Vitrectomy for Prevention of Macular Hole Study, 1991 – 1992.

Certified Surgeon: Pneumatic Retinopexy Clinical Trial II, 1990 – 1994.

Certified Surgeon: Silicone Oil Study, 1988 – 1994 (Porex, Co.).

B. Berger, M.D.

Page 17

Certified Surgeon, Collaborative Ocular Melanoma Study, 1987 – 1999.

Investigator Krypton-Argon Regression of Neovascularization Study, 1984 – 1991.

Committees:

Council Member, Gerson Lehman Group, 2012

Consultant. Guidepoint Global Advisors, 2012

Chief, Department of Ophthalmology, Seton Hospital, 1999 – 2001.

Chief, Department of Ophthalmology, Brackenridge Hospital, 1994.

Member, Membership Committee, Travis County Medical Society, 1993 – present.

Member, Texas Ophthalmology Association, Ad Hoc Committee for the Diabetes 2000 Project, 1992.

Judge, Miss Austin Beauty Pageant, April 1992.

Member, Disaster and Civil Defense Committee, Travis County Medical Society, 1991 – present.

Member, Laser Committee, Seton Hospital, 1988 – 1990.

Chairman, Texas Diabetes Control Project Advisory Committee, Texas Department of Health, 1987 – 1989

Member, Physician-Nurse Liaison Committee, Seton Hospital, 1989 – present.

Member, Special Committee on AIDS policy, Travis County Medical Society, 1989.

Chairman, Texas Diabetes Control Project Advisory Committee, Austin, Texas, 1987 – 1988.

Chief of Ophthalmology, St. David's Community Hospital, Austin, Texas, 1984 – 1986.

Executive Committee, St. David's Community Hospital, Austin, Texas, 1984 – 1986.

Research and Education Committee, Scott, Sherwood, and Brindley Foundation, Temple Texas, 1981 – 1983.

Presentations:

Update on Treatments for Diabetic Retinopathy: Clinically Relevant Results from the Diabetic Retinopathy Clinical Research Network. American Academy of Ophthalmology. Las Vegas, Nevada, November 2015.

Microvolume Drug Delivery: A Novel Therapeutic Strategy For Patients With Neovascular Age-Related Macular Degeneration (nAMD). Retina Society. Paris, France, October 2015

Phase I, Masked, Placebo-Controlled, Single and Multiple Ascending Intravenous Dose Studies Evaluating Systemic and Ocular Safety, Tolerability, and Visual Acuity Effects of RN6G (PF-04382923) in Subjects with Dry, Age-Related Macular Degeneration (ARMD). Associate for Research in

B. Berger, M.D.

Page 18

Vision and Ophthalmology Annual Meeting, Seattle, WA, May 2013.

DARPin® MP0112 Shows Extended VEGF Inhibition Effect in Diabetic Macular Edema, Retina Society Rome, Italy, September, 2011.

Radiation Treatment for AMD, International Masters of Retina, Cap Cana, Dominican Republic, Dominican Republic, February 14, 2011.

Rhegmatogenous Retinal Detachment Due to PDR: Evolution of Management, International Masters of Retina, Cap Cana, Dominican Republic, Dominican Republic, February 15, 2011.

Expanded Two-year Follow Up Of A Randomized Trial Evaluating Ranibizumab Plus Prompt Or Deferred Laser Or Triamcinolone Plus Prompt Laser For Diabetic Macular Edema, Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, FL, May 2011.

Advances in Minimally Invasive Surgery, SEO Congress, Madrid, Spain, September 2010.

New Drugs in Development for Retinal Diseases, SEO Congress, Madrid, Spain September 2010.

New Guidelines for the Treatment of Retinal Diseases, SEO Congress, Madrid, Spain, September 2010.

Transconjunctival Self-sealing Sclerotomy, The Retina Society Annual Scientific Meeting, Boston, MA, September 2007.

Allergan DME and RVO Study Presentations, December 2005.

Experimental Treatments for Macular Degeneration Grand Rounds Presentation, November 11, 2005

Genaera Study Presentation, November 2005.

Retisert Study Presentation, October 2005.

Cand5 Anti VEGF RNAi Evaluation Study Presentation, September 2005.

Dexamethasone Implant Effective Treatment for Persistent Macular Edema, Texas Ophthalmological Association, Austin, Texas, May 2004.

Fluocinolone Acetonide Implantation of Patients with Posterior Uveitis and Diabetic Retinopathy, Austin Ophthalmological Society, Austin, Texas, November 2002.

Fluocinolone Acetonide Implantation of Patients with Posterior Uveitis and Diabetic Retinopathy, Grand Rounds, University of Texas Health Science Center, San Antonio, Texas, August 2002.

New Treatment Techniques in Clinical Research for Chronic Inflammatory Retinal Disease, Grand Rounds, University of Texas Health Science Center, San Antonio, Texas, August 2001.

Posterior Uveitis Cases, Austin, Texas, March 2002.

The Prophylactic Treatment of Age-Related Macular Degeneration Clinical Trial, DMAE Update, Madrid, Spain, April 2001.

New Treatment Techniques for Retinal Diseases, Concepts and Controversies for the Practicing Ophthalmologist, San Antonio, Texas, February 2001.

B. Berger, M.D.

Page 19

New Treatments for Macular Degeneration, Texas Ophthalmology and Otorlanygology Annual Meeting, Austin, Texas, March 2000.

Anterior Vitrectomy Techniques for the Comprehensive Ophthalmologist, Grand Rounds at University of Texas Medical Branch at Galveston, September 1998.

Retinitis Update, Austin Ophthalmological Society, Austin, Texas, November 1995.

Management of Progressive Outer Retinal Necrosis in Acquired Immunodeficiency Syndrome, Vitreous Society, 13th Annual Meeting, London, England, August 1995.

Posterior Uveitis, Rotterdam Eye Hospital Grand Rounds, Rotterdam, Netherlands, February 1995.

Neuroretinitis in Patients with AIDS, American Uveitis Society Meeting, San Francisco, California, October 1994.

Ophthalmic Manifestations of Presumed Rifabutin-Related Uveitis, American Uveitis Society Meeting, San Francisco, California, 1994.

Characteristics, Natural History and Risk Factors to Progression in Eyes with Stage 2 Macular Holes, American Academy of Ophthalmology, San Francisco, California, November, 1994.

Baseline Vision Measurements in Patients with Macular Holes, American Academy of Ophthalmology, San Francisco, California, November 1994.

YAG Laser Membranotomy for Macular Hemorrhage From Macroaneurysm, Texas Ophthalmological Association 17th Annual Meeting, Houston, Texas, May 1993.

Posterior Uveitis, Grand Rounds, University of Texas Southwestern Medical Center, Dallas, Texas, February 1992.

Posterior Uveitis, Grand Rounds, Oschner Clinic, New Orleans, Louisiana, January 1992.

Miliary Toxoplasmic Retinitis in a Patient with AIDS. Vitreous Society 9th Annual Meeting, Paris, France, September 1991.

Posterior Uveitis, Grand Rounds, University of Texas Medical Branch, Galveston, Texas, December 1990.

Posterior Uveitis, Grand Rounds, University of Texas Southwestern Medical School, Dallas, Texas, December 1990.

The Management of Macular Hemorrhage from Macroaneurysms. Austin Ophthalmology Society, March 1990.

The Management of Macular Hemorrhage from Macroaneurysms. Vitreous Society 6th Annual Meeting, Orlando, Florida, December 1989.

Who's at Risk for Diabetic Retinopathy. Presented at Symposium on Complications of Diabetes. Texas Medical Association 1989, Annual Session, Forth Worth, Texas, May 1989.

Toxoplasmic Retinitis in AIDS. Vitreous Society 5th Annual Meeting, Scottsdale,

B. Berger, M.D.

Page 20

Arizona, December 1988.

AIDS: The Acquired Immunodeficiency Syndrome and Its Ophthalmic Manifestations. Texas Medical Association, San Antonio, Texas, May 1988.

Texas Diabetes Control Project. Texas Ophthalmological Association 32nd Annual Meeting, San Antonio, Texas, May 1988.

AIDS: The Acquired Immunodeficiency Syndrome and Its Ophthalmic Manifestations. American Academy of Ophthalmology, Dallas, Texas, November 1987.

Multifocal Choroiditis. American Uveitis Society. Dallas, Texas, November 1987.

Multiple Evanescent White Dot Syndrome. Texas Ophthalmological Association 31st Annual Meeting, Houston, Texas, May 1987.

Real Time Fundus Reflectometry Controlled Retinal Photocoagulation. Alamo Alumni Day Meeting, San Antonio, Texas, April 1987.

Real Time Fundus Reflectometry Controlled Retinal Photocoagulation. The Vitreous Society, Palm Springs, California, December 1986.

Retinal Cavernous Hemangiomas. Alamo Alumni Day Meeting, San Antonio, Texas, April 1986.

Retinal Cavernous Hemangiomas. The Medical College of Wisconsin Eye Institute Resident Alumni Meeting, Milwaukee, Wisconsin, June 1985.

Invasive Melanocytoma. Alamo City Alumni Day, San Antonio, Texas, April 1985.

Invasive Melanocytoma. Vitreo-Retinal Symposium, Lake Tahoe, California, February 1985.

Krypton Photocoagulation of Subretinal Neovascularization. Texas Ophthalmological Association 28th Annual Meeting, Fort Worth, Texas, May 1984.

Krypton Photocoagulation of Subretinal Neovascularization. Hawaiian Ophthalmological Society 5th Annual Meeting, Lahaina, Hawaii, January 1984.

Foveal Burn from Laser Iridotomy. Hawaiian Ophthalmological Society 5th Annual Meeting, Lahaina, Hawaii, January 1984.

Birdshot Retinochoroidopathy. American Uveitis Society Meeting, Chicago, Illinois, October 1983.

Posterior Uveitis. Austin Ophthalmological Society, Austin, Texas, September 1983.

Branch Vein Occlusion. E. Veirs Ophthalmology Conference, Temple, Texas, September 1983.

Complications of Epiretinal Membrane Surgery. Texas Ophthalmological Association 25th Annual Meeting, Dallas, Texas, May 1981.

Epiretinal Membrane Surgery; Hereditary Retinal Dystrophies. Veirs Ophthalmology Conference, Temple, Texas, May 1981.

B. Berger, M.D.

Page 21

Epiretinal Membranes. Austin Ophthalmology Society, Austin, Texas, April 1981.

Metastatic Endophthalmitis Complicating Neonatal Streptococcal Septicemia. Interim Meeting of the American Uveitis Society, South Lake Tahoe, Nevada, March 1981.

Posterior Choroidal Melanoma. Department of Ophthalmology, Quarterly Clinical Conference, University of Texas Southwestern Medical School, Dallas, Texas, January 1980.

Vitreous Loss Managed by Anterior Vitrectomy. Alumni Meeting Department of Ophthalmology, Medical College of Wisconsin, Milwaukee, Wisconsin, June 1980.

Preretinal Membrane Diseases and Surgical Management. Yale University College of Medicine Department of Ophthalmology and Visual Science Meeting, April 1980.

Anterior Segment Ischemia and Fuch's Heterochromatic Cyclitis. Interim Meeting of the American Uveitis Society, Phoenix, Arizona, March 1980.

Hereditary Retinal Dystrophies. Pediatric Ophthalmology Clinical Conference, Eye Institute of the Medical College of Wisconsin, Milwaukee, Wisconsin, October 1979.

Management of Vitreous Loss. Illinois Eye and Ear Infirmary, Residents/Alumni Day, 1979.

Long-Term Results of Vitreous Loss Managed by Anterior Vitrectomy. Sixth Biennial Cataract and Intraocular Lens Congress, Houston, Texas, December 3, 1978.

Bilateral Cytomegalovirus Panuveitis Following High Dose Steroid Therapy. Ocular Microbiology and Immunology Group Annual Meeting, Kansas City, Missouri, October 21, 1978.

Alopecia Universals and Cone-Rod Dystrophy. ISCERG Meeting, Ghent, Belgium, 1976.

Lung Cancer: Immunological Effects of Surgery and Radiation Therapy. Senior Scientific Session, University of Chicago School of Medicine Alumni Day, 1975.

Choroidal Vasculature Immunologic Responses Studied by Arterial Injection of Particulate Antigen. ARVO, Sarasota, Florida, 1975.

Video Presentations

Transconjunctival Self-sealing Sclerotomy, American Society of Retina Specialists 26th Annual Meeting, Maui, Hawaii, October 2008.

Removing Pseudophakic Precipitates with the Tano DDMS, Vitreous Society 18th Annual Meeting, Cancun, Mexico, January 2001.

Wide-Angle Endoillumination. Vitreous Society, St. Thomas, Virgin Islands, 1993.